The KMC8.8 monoclonal antibody was made by immunizing rats with the BMSZ stromal cell clone, and was selected for further study because of its ability to inhibit production of myeloid cells in Dexter cultures but not that of lymphoid cells in Whitlock-Wme cultures. The influence on myeloid progenitors might have been indirect, since the antibody did not prevent responsiveness to colony-stimulating factors in semisolid agar cultures. Furthermore, there was no inhibition, and some augmentation, of cell production when the antibody was added to established Dexter cultures. A cDNA clone that encoded the KMC8.8-recognized molecule was isolated by expression cloning and found to be identical in sequence to a previously published murine CD9 homologue.
The antibody and cDNA clone were used to establish that CD9 is expressed by stromal cells, megakaryocytes, platelets, myeloid cells, and subpopulations of mature lymphocytes in mice. Treatment with the KMC8. 8 perimental approach in which monoclonal antibodies were developed and selected for the ability to block cell adhesion or blood cell formation. The nature of molecules recognized by these reagents was then determined. A similar strategy was used to produce an antibody that selectively blocks formation of myeloid cells in culture, and we now demonstrate that it recognizes the murine homologue of CD9. Previous studies have implicated this interesting molecule in proadhesive responses of human platelets and lymphocyte^.^^'^ Its expression and ligation has also influenced adhesion, migration, and growth of other cell types."*" A similar explanation could account for the ability of CD9 antibody to interfere with myelopoiesis, which would suggest that blood cell formation requires adhesive cell interactions that are both appropriate and timely. Antibodies that either decrease or increase adhesion can upset this delicate process.
MATERIALS AND METHODS
Cells. BMS2, a stromal cell clone, was maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (GIBCO, Grand Island, NY) and 5 X lo-' m o m 2-mercaptoethanol (2ME). WEHI3, a myelomonocyte line, was maintained in Iscove's medium supplemented with 10% fetal calf serum and 5 X m o m 2ME. 293T, a renal cell carcinoma cell line, was kindly provided by Dr T. Hirano (Osaka University, Osaka, Japan) and maintained in DMEM supplemented with 10% fetal calf serum. SP2/0, a mouse myeloma cell line, was maintained in RPM1 1640 supplemented with 10% fetal calf serum and 5 X lo-' m o m 2ME. Stromal cell clones (BMNS1, OP42, SSl, +/+2.4, PA6, and 3T3L1), lymphoma cell lines (702/3, 18.81, 40E, 2.6.2, BCB14, WEHI279, WEHI231, BCL1, CH12, BAL17, BF0.3, and EM), a multipotential cell line (FDCP.CL21). a mastocytoma cell line (P815). an erythroleukemia cell line (GM86). a melanoma cell line (B16F10), an aorta endothelial line (H), and a neuroblastoma cell line (N2A) were maintained as previously de~cribed.~ Preparation of monoclonal antibodies. Rats were immunized intraperitoneally with BMSZ cells (1 X lo7 per rat) emulsified in complete or incomplete Freund's adjuvant (DIFCO, Detroit, MI) at 3-week intervals. Four days after the last injection, spleen cells were fused with S W 0 cells by using polyethylene glycol 4000 and were cultured in the presence of hypoxanthine-aminopterin-thymidine (Sigma, St Louis, MO). Antibodies that reacted with BMS2 cells by enzyme-linked immunosorbent assay (ELISA) but not with spleen cells by flow cytometry analysis were screened, and hybridomas BMS2 cell monolayers. After a 30-minute co-culture, unbound cells were removed by three washes. Before each aspiration, plates were vigorously agitated on a vortex mixer. Bound cells thus recovered were pooled and counted. The percentage of bound cells was determined as follows: percent bound = 100 X number of bound cells/ number of cells applied to each well. Pretreatment with KMC8.8 was performed at the indicated times.
Expression cloning and sequence analysis. Polyadenylated RNA was isolated from BMS2 cells with a Fast Track mRNA isolation kit (Invitrogen, San Diego, CA). Double-stranded cDNA was synthesized with a Timesaver cDNA synthesis kit (Pharmacia, Uppsala, Sweden), ligated with BstXI adaptors (Invitrogen), and cloned into a mammalian expression vector, PEF-BOS.'~ This vector was a kind gift from Dr S. Nagata (Osaka Bioscience Institute, Osaka, Japan). Plasmid DNAs were purified from pools of a few thousand cDNA clones each and were transfected into 293T cells by a standard calcium phosphate precipitation method. A positive pool was identified by reactivity for KMC8.8 on a FACScan and divided into progressively smaller pools and rescreened until a single cDNA was isolated. The insert of a single clone was subcloned into pBluescript (Stratagene, La Jolla, CA), and the nucleotide sequence was determined using a Sequenase version 2.0 DNA sequencing kit (USB, Cleveland, OH). Nucleotide database searching was then performed with FASTA from the GCG computer program (Genetics Computer Group, Madison, WI).
Norrhern blot analysis. Total RNAs were isolated by the method of Chomczynski and Sacchi,I7 electrophoresed through formaldehyde agarose gels, and transferred onto a nylon membrane (Hybond-N; Amersham, Arlington Heights, IL). Probes were labeled by random priming (Amersham) and used for hybridization.
RESULTS
Modulation of myelopoiesis in long-term bone marrow cultures. The KMC8.8 antibody resulted from immunization with the BMS2 stromal cell clone and initial selection with a cell-based ELISA assay as detailed earlier. Antibodies from this fusion that recognized appreciable numbers of viable spleen cells were discarded, as were those found by immunoperoxidase staining to detect only intracellular antigens. Further screening then involved addition of antibodies to long-term bone marrow cultures. One of these antibodies, designated KMC8.8, completely blocked production of myeloid cells in Dexter cultures (Fig 1) . In contrast, no significant changes were observed when KMC8.8 was included in Whitlock-Witte cultures, which normally sustain growth of lymphoid cells (Fig 1) . The morphology of adherent layers in long-term bone marrow cultures seemed unaffected by KMC8.8, and treated cultures contained the usual collection of adipocytes, stromal cells, and macrophages. However, typical "cobblestone" areas of hematopoiesis were absent, suggesting that precursors might not be simply sequestered in the adherent layer. The antibody was then added to established Dexter cultures (4 to 6 weeks after initiation) and found not to suppress ongoing myelopoiesis. On the contrary, KMC8.8 substantially increased the number of nonadherent cells (average of 1.8-fold in two experiments) within 1 week of addition ( this antibody could be involved in some aspects of myeloid but not lymphoid cell production.
Distribution of the antigen detected by KMC8.8. Twocolor flow cytometry analyses revealed that KMC8.8 recognized large numbers of myeloid cells in bone marrow. Cells gated for bright KMC8.8 staining had large forward and orthogonal light-scatter profiles and most of them expressed Mac-l (CDllb) and GR1 (Ly-6G) antigens (Fig 2) . However, there was not complete concordance in staining obtained with these markers, suggesting that KMC8.8 might detect a previously unrecognized myeloid cell marker. Erythroid cells in bone marrow that were detected with the TERl19 antibody were not stained by the KMC8.8 antibody, and the same was true for most lymphoid cells recognized by antibodies to Thyl.2, CD45RA, or surface IgM (Fig 2) . However, subpopulations of mature T and B lymphocytes in spleen expressed moderate amounts of KMC8.8 antigen (Fig 3) . Immunoperoxidase staining of bone marrow sections showed extensive staining of myeloid and stromal elements, as well as megakaryocytes (results not shown). The latter finding prompted a two-color analysis of peripheral blood using the 4A5 monoclonal antibody to positively identify platelets. This revealed that murine platelets are also positive for the KMC8.8 antigen (Fig 4A) . Neutrophils elicited as peritoneal exudate cells or in peripheral blood displayed the KMC8.8 antigen, consistent with its expression on myeloid cells in marrow ( Fig 4B and see below) . Direct addition of KMC8.8 antibody to semisolid agar cultures did not influence the proliferation of myeloid progenitor cells ( Table 2) . Expression of KMC8.8 on lymphohemopoietic progenitor cells was further investigated by flow cytometry and sorting, followed by culture of the fractions in semisolid agar. Cells with the brightest staining were predominantly neutrophils (78%) and other relatively mature myeloid cells (21%; Fig 5A) . Although cells with dim KMC8.8 staining were also predominately myeloid (69%), this fraction also contained some lymphocytes (29%). In contrast, the fraction that lacked detectable KMC8.8 was enriched for cells in lymphoid (70%) and erythroid (22%) lineages (Fig 5C) . Staining of bone marrow alone did not alter the subsequent cloning efficiency in lymphoid or myeloid progenitor assays (data not shown). Thus, simple arrest of precursor replication as a result of antigen ligation does not explain the ability of the antibody to totally block longterm cultures. Most of the IL-7-responsive B-cell precursors were found within the KMC8.8-negative fraction, whereas cells with dim expression of this marker were enriched threefold to fourfold for myeloid precursors (Table 3) . Screening of a panel of cell lines revealed that all of six stromal cell clones (BMS2, BMNS1, OP42, SS1, +/+2.4, and PA6) were positive (Table 4 ). Other lines with greater than background expression included a neuroblastoma (N2A), a fibroblast/preadipocyte (3T3L1), a melanoma (B16F10), and an aortic endothelial line (P9). Hematopoietic cell lines that were at least weakly positive included an erythroleukemia (GM86), two lymphomas (WEHI23 1 and BF0.3), and a multipotential cell line (FDCP.CL21). A large number of lymphomas (70213, 18.81, 40E, 2.6.2, BCB14, WEHI279, BCL1, CH12, BAL17, and EL4) were negative, as was a myelomonocytic leukemia (WEHI3) and a mastocytoma (P815).
Immunoprecipation (data not shown) and immunoblotting revealed that the antigen recognized by KMC8.8 was approximately 24 kD in size in most tissues, with a distinctive doublet of 24-kD and 21-kD species being found only in the spleen (Fig 6) . The liver was the only one of many tissue extracts examined in which the antigen was not easily demonstrated. These observations reveal the KMC8.8 antigen to be widely distributed in murine tissues and to be expressed at least on platelets, as well as stromal, myeloid, and neuronal cells. It was absent from most B-lineage lymphocyte precursors, but present at low levels on cells destined to become neutrophils.
KMC8.8 antibody recognizes the murine homologue of CD9. The size and tissue distribution of the antigen recognized by KMC8.8 did not precisely correspond to descriptions of any known cell surface glycoprotein in mice or men. Therefore, an efficient expression cloning technique was used for molecular characterization." This involved transient expression in human renal carcinoma cells of pools prepared from a library made with BMS2 mRNA as detailed earlier.
This resulted in a single full-length cDNA clone, Y-1-4-34, that encoded the KMC8.8-recognized molecule (Fig 7A) . The cDNA sequence was then determined and found to be completely identical to that previously reported for a murine CD9 cDNA'* (data not shown). When 293T cells were transfected with this Y-1-4-34 clone, they expressed a molecule recognized by KMC8.8, which was similar in size to that immunoprecipitated from the surface of BMS2 cells (Fig 7B) . Northern blot analysis (Fig 7C) . This pattern observed by Northern blot analysis was identical to the KMC8.8 staining data. Thus, we conclude that KMC8.8 recognizes the murine homologue of CD9.
Northern blots were also used to confirm and extend the tissue distribution of murine CD9 (Fig 8) . As expected, it was widely expressed in both hematopoietic and nonhematopoietic organs, including the brain, lung, heart, thymus, spleen, kidney, liver, and bone marrow. Expression of CD9 mRNA was particularly high in lung and bone marrow. In contrast, the thymus and heart contained low levels of CD9 transcripts.
Ligation of CD9 promotes adhesion between myeloid and stromal cells. As noted earlier, KMC8.8 antibody had no influence on clonal proliferation of myeloid progenitor cells ( Bone marrow cells were stained with KMC8.8 antigen and sorted into completely negative, dull positive, and bright positive fractions. The resolution of these populations is illustrated in Fig 2, and c~l e s .~~' The WEHI3 myelomonocytic leukema displayed low but significant binding to BMS2 stromal cells, and this was substantially augmented by treatment with KMC8.8 ( Table 5 ) . The response was only observed when BMS2 cells were exposed to the antibody, consistent with the inability to detect antigen on WEHI3 cells by staining ( Table 4) . The KM16 antibody, which recognizes the integrin p, chain (CD29). can recognize both WEHI3 and BMS2 cells. It did not deliver this proadhesive stimulus and was used as a negative control. KMC8.8 antibody also caused a small but reproducible increase in adhesiveness between normal bone marrow cells and the BMS2 stromal cell clone ( Table 6 ). The increment was again greatest when stromal cells were exposed to the antibody, but the proportion of myeloid it recognized the murine homologue of CD9. This member of the "transmembrane 4" (TM4) or "tetraspan" family of membrane glycoproteins has been characterized on many cell types and in multiple species and functional contexts.'" Furthermore, CD9 was found to deliver a proadhesive stimulus in many of those studies. Treatment of platelets, a megakaryocyte line, or pre-B cell lines with CD9 antibodies resulted in homotypic aggregation while the migration of tumor cells was inhibited."-". For provides a possible explanation for its ability to block myelopoiesis in long-term bone marrow cultures. Further study might reveal physical and functional associations between CD9. integrins, and intracellular mediators that could be involved in hematopoiesis.'.'''.'~.~~ Whereas addition of KMC8.8 antibody at the initiation of long-term bone marrow cultures totally arrested production of myeloid cells, it augmented myelopoiesis in previously established (4 to 6-week) cultures. Antibodies to CD44 were also only effective blockers when added at the beginning of culture, but displayed no specificity for suppression of myeloid
Physically dispersed bone marrow essentially represents wounded tissue. Extensive remodeling of microenvironments and sorting of hematopoietic stem cells into appropriate niches must be required after transfer to culture, a phase that seems particularly sensitive to these types of antibodies. CD9 is a putative receptor for feline immunodeficiency virus, and acute infection proceeds through transient elevation of myeloid progenitors to severe neutropenia.*'.*' This may provide an in vivo corollary to our findings that CD9 ligation influences myelopoiesis in culture.
There are at least 15 members of the TM4 superfamily, and these proteins are thought to traverse the membrane four times with both the amino-and carboxyl-terminal portions internalized." Although these proteins are widely distributed and implicated in a variety of functions, they do have some common features. Many of these molecules are upregulated on activated cells, and their ligation via particular antibodies can stimulate growth, promote adhesion, andor inhibit migration." Murine CD9 is consistent with this pattern in that it delivered a proadhesive stimulus for stromal cell-myeloid cell recognition. Constant movement and transient interactions between cells in long-term bone marrow cultures have been documented by time-lapse ~inematography.'.~~ If the CD9 antibody mimics some normal ligand, it may deliver an artificially sustained, rather than transient stimulus.
Other clues to the function of CD9 may come from its participation in macromolecular protein complexes on the cell s u~a c e .~n . m~.~9 It can physically associate with integrins on platelets and lymphocytes, with a possible preference on the latter cell type for the integrin p, chain.'" We found that CD9 was immunoprecipitated alone from stromal cell extracts made with Triton detergent, but more complex patterns were obtained with the mild detergent, digitonin. However, it was not possible to demonstrate p, chains in these preparations (data not shown). Further study might reveal that the composition of CD9-containing protein complexes is cell type-, or activation state-, dependent. Alternatively, their detection could require particular extraction and precipitation conditions.
The ability of CD9 to transmit proadhesive signals may depend in part on its association with small G protein^.'^
org From
Another interesting association has been found with the transmembrane precursor of heparin-binding epidermal growth factor, which is also used as the receptor for diptheria to~in.'~.'~ If stromal cell CD9 is associated with growth factors, disruption of this relationship might also account for the influence of antibodies on myelopoiesis in culture. Our antibody had no direct inhibitory effect on myeloid progenitors in semisolid agar, suggesting that it only influences stromal cell-dependent events. Earlier studies showed that human CFU-C and BFU-E were also unaffected by CD9 antib~dies.~' Although the murine WEHD myelomonocytic leukemia expressed little or no CD9, its adhesion to antibody-treated stromal cells was enhanced. We were unable to attribute this binding to CD44, CD106, or CD54 (data not shown). This differs from the CD9-enhanced adhesion of human pre-B lymphoma cells to bone marrow-derived fibroblasts." In that circumstance, fibroblasts lacked CD9 and treatment of the lymphoma apparently activated VLA-4 and VLA-5 to recognize fibronectin. Human endothelial cells are constitutively positive for CD9, and ligation of the molecule by antibodies promotes adhesion of neutrophils.3'
Human pre-B cells are also CD9+ and induced to adhere to human marrow fibroblasts by CD9 ligation." This led to the suggestion that loss of CD9 with maturation of human pre-B cells might diminish their adhesiveness for marrow stromal cells. Activation of mature human B cells might result in its reexpression, because CD9 has been detected in germinal centers.32 However, the situation is apparently reversed in mice, in which CD9 was not detectable on pre-B cells but was expressed on subpopulations of splenic lymphocytes. Substantial constitutive adhesion between murine pre-B cells and stromal cells prevented an assessment of the CD9 contribution to this interaction, but the antibody had no effect on lymphocyte production in long-term cultures. CD9 has not been described as a conspicuous marker on normal neutrophil granulocytes of humans, being restricted to eosinophils and basophils in blood.30s33-35 In contrast, we found that myeloid cells in the marrow, peritoneal exudate, and peripheral blood of mice were strongly positive for CD9. The feline homologue of CD9 is also highly expressed on monocytes and granulocytes in peripheral bl00d.'~ It will be interesting to determine if human marrow stromal cells display this molecule.
Tissue distribution of murine CD9 was investigated at both mRNA and protein levels. In most cases, there was concordance between the two. A single mRNA species of approximately 1.3 kb was found in all tissues. With the exception of the spleen, we immunoprecipated a single protein of approximately 24 kD. A doublet was found in that tissue, and second bands have been described in some human cells.34 In that case, size heterogeneity was attributed to differences in either glycosylation or covalent lipid attachment. This feature was shared with a murine kidney tubular antigen, which was similar in many respects to CD9, except for its absence from platelet^.^^ As far as we are aware, KMC8.8 is the only reagent known to recognize the murine homologue of CD9. While we detected CD9 mRNA in the liver, almost no protein was demonstrated from that tissue. This could have been due to protein degradation or posttranscriptional control over expression. The liver sample could also have contained substantial amounts of blood. Neither CD9 protein or mRNA were significantly expressed in adult liver of rats.""* Conversely, there was relatively little CD9 mRNA but abundant protein in the heart, which might also be attributed to blood contamination in one sample or mRNA degradation in another.
Cell interaction molecules expressed in bone marrow may have multiple roles in other tissues.' As one example, whereas the VLA-4 and VCA"1 pair of molecules probably mediate pre-B cell recognition of marrow stromal cells, they have been implicated in implantation and other critical embryonic events, as well as a variety of processes involving leukocyte migration and inflammation in ad~lts.~.'"~' CD9 may also have multiple roles in various organs, and KMC8.8 antibody provides an important tool for its investigation in mice.
